Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 1894-1900

  Sharma, Ricky A ^a   McLelland, Heather R ^a   Hill, Kirsti A ^a   Euden, Stephanie A ^a   Steward, William P ^a   Gescher, Andreas J ^a   Ireson, Christopher R ^a   Manson, Margaret M ^a   Pirmohamed, Munir ^b   Marnett, Lawrence J ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMA EXTRACT; CURCUMIN; DRUG METABOLITE; GLUTATHIONE TRANSFERASE; MALONALDEHYDE; P54FP; PLANT EXTRACT; POLYPHENOL; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CELL; CANCER PREVENTION; CANCER STAGING; COLORECTAL CANCER; DNA ADDUCT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FECES LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; CURCUMIN; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NAUSEA; PILOT PROJECTS; PLANT EXTRACTS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 0034772953     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Strategy and planning for chemopreentive drug development: Clinical development plans II
2. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound
3. Chemopreventative effect of curcumin, anaturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer
4. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis
5. Turmeric and curcumin as topical agents in cancer therapy
6. Cancer statistics 2000
7. Mechanisms of anticarcinogenic properties of curcumin: The effect of curcumin on glutathione linked detoxification enzymes in rat liver
8. Induction of glutathione S-transferase activity by curcumin in mice
9. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colonmucosa: Relationship with drug levels
10. Diminution of singlet oxygen induced DNA damage by curcumin and related antioxidants
11. Studies on curcumincurcuminoids. XXII. Curcumin as a reducing agent and as a radical scavenger
12. Oxygen radical scavenging activity of curcumin
13. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron
14. Cytotoxic and cytoprotective activities of curcumin
15. Anti-inflammatory and irritant activities of curcumin analogues in rats
16. Lipid peroxide formation in experimental inflammation
17. Characterization of metabolites of the chemopreventive agent curcumin in humans and rat hepatocytes and in rat plasma and evaluation of their ability to inhibit cyclooxygenase-2 expression
18. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex
19. The metabolism and excretion of curcumin (1,7 -bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat
20. A study on the fate of curcumin in the rat
21. The glutathione S-transferase supergene family: Regulation of GST and contribution of the isoenzymes to cancer chemoprevention and drug resistance
22. Glutathione S-transferase πin colorectal tumors is predictive for overall survival
23. Gluathione-associated enzymes in anticancer drug resistance
24. Lipid peroxidation: DNA damage by malondialdehyde
25. Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthase
26. Cyclooxygenase-2 inhibitors in tumorigenesis (part II)
27. Lipid peroxidation and prostaglandins in colorectal cancer
28. Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues
29. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology
30. Glutathione S-transferases
31. No association between tacrine transaminitis and the glutathione transferase θ genotype in patients with Alzheimer's disease
32. Identification of genetic polymorphisms at the glutathione S-transferase π locus and association with susceptibility to bladder, testicular and prostate cancer
33. Development of monoclonal antibodies to the malondialdehyde-deoxyguanosine adduct, pyrimidopurinone
34. Determination of malondialdehyde-induced DNA damage in human tissues using an immunoslot blot assay
35. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers
36. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane)
37. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with post-operative inflammation
38. Phase I chemoprevention clinical trial of curcumin
39. Influence of turmeric and curcumin on growth, blood constituents and serum enzymes in rats
40. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers
41. In vitro studies on the intestinal absorption of curcumin in rats
42. Age and gender dependent levels of glutathione and glutathione S-transferases in human lymphocytes
43. Glutathione S-transferase activity and glutathione S-transferase μ expression in subjects at risk for colorectal cancer
44. Determination of DNA adducts of malondialdehyde in humans: Effects of dietary fatty acid composition
45. Gluathione S-transferase mu in human lymphocyte and liver: Role in modulating formation of carcinogen-derived DNA adducts